Skip to content

Depression: all studies

Page 295 of 1,034: studies 2,941 to 2,950 of 10,336, newest first. Back to the depression overview

Research

Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression

Psychopharmacology August 3, 2016 Bangkun Yang, Ji-Chun Zhang, Mei Han et al. 93 citations

RATIONALE: The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression. OBJECTIVE: We compared the rapid and sustained antidepressant effects of R-ketamine and rapastinel in the social defeat stress model. RESULTS: In the tail suspension and forced swimming tests, R-ketamine (10...

DOI: 10.1007/s00213-016-4399-2 (opens in new tab) Full text (opens in new tab) Ketamine Social defeat Behavioural despair test Nmda receptor +11

The Effects of Mindfulness-Based Cognitive Therapy and Cognitive Behavioral Analysis System of Psychotherapy added to Treatment as Usual on suicidal ideation in chronic depression: Results of a randomized-clinical trial.

Journal of Affective Disorders August 2016 Thomas Forkmann, Eva‐lotta Brakemeier, Tobias Teismann et al.

Suicidal ideation (SI) is common in chronic depression, but only limited evidence exists for the assumption that psychological treatments for depression are effective for reducing SI. In the present study, the effects of Mindfulness-based Cognitive Therapy (MBCT; group version) plus treatment-as-usual (TAU: individual treatment by either a psychiatrist or a licensed psychotherapist, including...

DOI: 10.1016/j.jad.2016.01.047 (opens in new tab) Full text (opens in new tab) Chronic depression Mindfulness-based cognitive therapy Persistent depression Rct +1

Should ketamine be used for the clinical treatment of depression?

Australasian Psychiatry August 1, 2016 Shalini Arunogiri, Nicholas A Keks, Judy Hope

Objective: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. Conclusions: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years....

KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.

Depression and Anxiety August 2016 William V Bobo, Jennifer L. Vande Voort, Paul E Croarkin et al.

There is an urgent need for more rapidly effective pharmacotherapies for major depressive disorder and bipolar disorder (BP) that are efficacious and tolerable for depressed patients who respond poorly to conventional treatments. Multiple controlled trials have now demonstrated a rapid, nonsustained antidepressive response to a single intravenous infusion of ketamine. Early controlled studies...

Repeated intravenous ketamine benefits patients with treatment‐resistant depression

The Brown University Psychopharmacology Update August 1, 2016

Intravenous ketamine administered twice a week or three times a week resulted in sustained antidepressant effects compared with placebo in a group of patients with treatment‐resistant depression, a new study has found. Based on similar results between the two dosing frequencies, the researchers indicated that a twice‐weekly regimen could serve as an initial repeated‐dose strategy in this...

Using Oral and Intranasal Dosage Forms of Ketamine for Managing Treatment-Resistant Depression: A Review of the Literature

International Journal of Medical Students July 27, 2016 Patrick Arthur Twohig, Vaughn Huckfeldt

A lack of effective treatment for patients with treatment-resistant depression (TRD) has led to the evaluation of ketamine, an N-methyl- D-aspartate receptor antagonist. Despite the demonstrated short-term benefits of using intravenous (IV) ketamine, side effects and the difficulty in administering ketamine outside the health-care setting has raised interest in alternative dosage forms....

Effectiveness of Mindfulness Training in Enhancing Executive Function and Decreasing Symptoms of Depression and Anxiety in Patients with Multiple Sclerosis (MS)

July 22, 2016 M. Amiri, M. Rabiei, V. Donyavi

The purpose of the present study was to evaluate the effectiveness of mindfulness training in enhancing executive function and decreasing symptoms of depression and anxiety in multiple sclerosis patients. The population in this study consisted of people with MS who referred to Karaj city MS society in 1394. These people didn’t experience medicinal changes during the study period and their...

The Relationship between Mindfulness and Cognitive Emotion Regulation and Depression among University Students

International Journal of Academic Research in Psychology July 15, 2016 Majid Sadoughi, Fatemeh Hesampour 2 citations

Admission at university can be considered as a critical phase in life of young students, leading them to enter a greater society and experience a different educational, social, and cultural setting.Generally, these drastic changes in their personal and social lives would be accompanied by intense anxiety and stress, negatively influencing their performance and efficiency; as a result, their...

Turning Towards or Turning Away: A Comparison of Mindfulness Meditation and Guided Imagery Relaxation in Patients with Acute Depression.

Behavioural and Cognitive Psychotherapy July 2016 Ana Costa, Thorsten Barnhofer

Disengaging from maladaptive thinking is an important imperative in the treatment of depression. Mindfulness training is aimed at helping patients acquire relevant skills for this purpose. It remains unclear, however, whether this practice is helpful when patients are acutely depressed. In order to investigate effects of mindfulness on symptoms and self-regulatory capacities in this group, the...

Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression

Acta Psychiatrica Scandinavica July 1, 2016 C. Loo, Verònica Gálvez, E. O'Keefe et al.

This pilot study assessed the feasibility, efficacy and safety of an individual dose‐titration approach, and of the intravenous (IV), intramuscular (IM) and subcutaneous (SC) routes for treating depression with ketamine.